Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle

Circulation

Volumn 99, Issue 16, 1999, Pages 2164-2170

  Gallo, Richard ^a   Padurean, Adrian ^a   Jayaraman, Thottala ^c   Marx, Steven ^c   Roque, Merce ^a   Adelman, Steven ^d   Chesebro, James ^a   Fallon, John ^b   Fuster, Valentin ^a   Marks, Andrew ^c   Badimon, Juan José ^a,b  

^a Cardiovasc Biol Res Laboratory   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d PFIZER INC   (United States)

Author keywords

Angioplasty; Cells; Restenosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27; RAPAMYCIN; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DRUG MECHANISM; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0033609090     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.16.2164     Document Type: Article

References (42)

1. Popma J, Califf R, Topol E. Clinical trials of restenosis after PTCA. Circulation. 1991;84:1426-1436.
2. Landau C, Lange R, Hillis L. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994;330:981-993.
3. Fuster V, Falk E, Fallon J, Badimon L, Chesebro J, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost. 1995;74:552-559.
4. Foegh M, Virmani R. Molecular biology of intimai proliferation. Curr Opin Cardiol. 1993;8:938-955.
5. 1 transition in VSMC. Mol Cell Biol. 1993;13: 3722-3733.
6. Cascells W, Lappi D, Bird A. Molecular atherectomy for restenosis. Trends Cardiovasc Med. 1993;156:48-55.
7. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau V. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-1464.
8. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in VSMC. Circ Res. 1995;76: 412-417.
9. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
10. Serrano M, Hannon GH, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366: 704-707.
11. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 CDK-interacting protein cip1 is a potent inhibitor of cyclin kinases. Cell. 1993;75:805-816.
12. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78: 59-66.
13. Chang M, Barr E, Lu M, Barton K, Leiden J. Adenovirus-mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular SMC proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96: 2260-2268.
14. Chen D, Krasinki K, Chen D, Sylvester A, Nisen PD, Andres V. Down-regulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in VSMC by p27, an inhibitor of neointima formation in the rat carotid artery. J Clin Invest. 1997;99:2334-2341.
15. Reynisdottir I, Polyak K, Iavaronne A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 1995;9:1831-1845.
16. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. Interleukin-2 mediated elimination of the p27 kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond). 1994;372:570-573.
17. kip1. Mol Cell Biol. 1996;16:6744-6751.
18. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits VSMC migration. J Clin Invest. 1996;98:2277-2283.
19. Gregory C, Huie P, Billingham M, Morris R. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation. 1993;55:1409-1418.
20. Meiser B, Billingham M, Morris R. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet. 1991;338:1297-1298.
21. Gallo R, Padurean A, Toschi V, Bichler J, Fallon J, Chesebro J, Fuster V, Badimon J. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation. 1998;97: 581-588.
22. Jayaraman T, Marks AR. Rapamycin-FKBP blocks proliferation, induces differentiation and inhibits cdc2 kinase activity in a myogenic cell line. J Biol Chem. 1993;268:25385-25388.
23. Almond PS, Moss A, Nakhleh RE, Melin M, Chen S, Salazar A, Chirabe K, Matas AJ. Rapamycin: immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model. Transplantation. 1993;56:275-281.
24. Schreiber S. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991;251:283-287.
25. Brown EJ, Schreiber S. A signaling pathway to control translational control. Cell. 1996;86:517-520.
26. Chen PL, Scully P, Shew JY, Want JY, Lee WH. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell. 1989;58:1193-1198.
27. Cordon C. Mutation of cell cycle regulators. Am J Pathol. 1995;147: 545-560.
28. Muller DW, Ellis S, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418-432.
29. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis after PTCA: a practical proliferative model in porcine coronary arteries. Circulation. 1990;82:2190-2200.
30. Fuster V, Badimon L, Badimon JJ, Ip J, Chesebro JH. The porcine model for the understanding of thrombogenesis and atherogenesis. Mayo Clinic Proc. 1991;66:818-831.
31. Wilcox JN. Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. Am J Cardiol. 1993;72:88E-95E.
32. Muller DW, Ellis SG, Topol EJ. Colchicine and antineoplastic therapy for the prevention of restenosis after PTCA. J Am Coll Cardiol. 1991;17: 126B-131B.
33. Thornton MA, Gruentzig A, Hollman J, King S, Douglas J. Coumadin and aspirin in prevention of recurrence after PTCA: a randomized trial. Circulation. 1984;69:721-727.
34. Group MS. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after PTCA? Results of the MERCATOR study. Circulation. 1992;86:100-110.
35. Ellis SG, Roubin G, Wilentz J, Douglas J, King SB. Effect of the 18-24 hour heparin administration for prevention of restenosis after uncomplicated PTCA. Am Heart J. 1989;117:777-782.
36. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimai arterial SMC accumulation in vivo. Nature. 1992;359:67-70.
37. Villa AE, Guzman LA, Garrel CL, Poptic EJ, Labhasetwar V, DiSousa S, Farrell CL, Plow EF, Levy RJ, DiCorleto PE, Topol EJ. Effects of antisense c-myb oligonucleotides on VSMC proliferation and response to arterial wall injury. Circ Res. 1995;76:505-513.
38. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science. 1993;261:1004-1012.
39. Epstein SE, Speir E, Finkel T. Do antisense approaches to the problem of restenosis make sense? Circulation. 1993;88:1351-1353.
40. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced VSMC accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 1994;91: 10732-10736.
41. Chang MW, Ohno T, Gordon D, Lu MN, Nabel GJ, Nabel EJ, Leiden JM. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits VSMC proliferation and neointima for-mation following angioplasty of the rat carotid artery. Mol Med. 1995;1:172-181.
42. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EJ. Gene therapy for VSMC proliferation after arterial injury. Science. 1994;265:781-784.